.Attribute Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after a median follow-up of 11 months, individuals along with metastatic intestinal tumors that obtained biomarker-matched treatments based upon distributing lump DNA profiling revealed a higher clinical benefit than those acquiring unrivaled treatment.